$ATNMOct 16, 2026, 8:31 AM ETAI processed
ATNM-400 shows broad preclinical activity in NSCLC, colorectal and ovarian models; data to be presented at EANM
AI Summary
Actinium (ATNM) will present preclinical EANM 2026 data showing its Actinium-225 radioconjugate ATNM-400 produced antitumor activity across KRAS- and ALK-driven NSCLC (including resistant models), improved responses in colorectal xenografts when combined with bevacizumab+oxaliplatin, and durable single-agent activity in ovarian models including bevacizumab-refractory tumors. These are preclinical xenograft results that the company says support a mutation-agnostic, pan‑tumor development strategy and both monotherapy and combination approaches, but no clinical efficacy or safety data were reported yet.
Positives
- ATNM-400 showed antitumor activity in KRAS- and ALK-driven NSCLC models, supporting a potential mutation-agnostic approach
- Combination data showed enhanced responses in colorectal models with bevacizumab + oxaliplatin
- Durable monotherapy activity observed in ovarian models, including bevacizumab-refractory tumors
Negatives
- All results are preclinical (xenograft) data, not clinical human data
- No clinical efficacy or safety information disclosed to assess translatability
- Responses came from specific models (e.g., moderate target expression in HCT15), so patient translation is uncertain